Generate:Biomedicines (NASDAQ: GENB), the drug developer focused on creating immunology and inflammation (I&I) and oncology treatments through its own artificial intelligence (AI)-based platform, has ...

Generate Biomedicines shares dropped nearly 21% Friday after the company’s $400 million initial public offering, continuing an uneven recovery for biotech stock-market debuts. After a biotech IPO ...

Despite wide availability of biologic drugs for asthma, use of these injectable medicines remains low — patients just dislike frequent injections. Generate Biomedicine’s lead drug candidate could ...

AI drug discovery specialist Generate Biomedicines has raised $400 million in the year’s largest initial public offering to date for a biotechnology firm. The company, which was launched in 2018 by ...

Shares of Recursion Pharmaceuticals (RXRX) spiked on Wednesday after the AI-driven drug developer significantly exceeded Street forecasts with its Q4 2025 financials, thanks primarily to a milestone ...

Boolean options: -n, --dry-run Don't actually minify the file(s), just show if they will be processed. -d, --include-dotfolders Include dotfolders in file search. -D, --include-dotfiles Include ...

Generate Biomedicines Inc., a biotechnology firm using artificial intelligence in drug development, is seeking to raise as much as $425 million in an initial public offering, as listing activity in ...

Add Yahoo as a preferred source to see more of our stories on Google. Researchers have demonstrated a particulate static effect-induced electricity generation technology inspired by the Tesla turbine.

Seedance 2.0 can take camera movement, visual effects, and motion into account. Seedance 2.0 can take camera movement, visual effects, and motion into account. is a news writer who covers the ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Generate:Biomedicines raised ...

Generate Biomedicines Inc. filed for an initial public offering, joining a growing list of biotechnology firms to leap to public markets as investors embrace the sector. The Somerville, ...